This document is an excerpt from the EUR-Lex website
Document 52023XC0131(03)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 December 2022 to 31 December 2022 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 December 2022 to 31 December 2022 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 December 2022 to 31 December 2022 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council)
PUB/2023/87
OJ C 37, 31.1.2023, p. 1–12
(BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
31.1.2023 |
EN |
Official Journal of the European Union |
C 37/1 |
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 December 2022 to 31 December 2022
(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1) or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council (2))
(2023/C 37/01)
— Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
Date of the decision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
||
2.12.2022 |
Mycapssa |
octreotide |
|
EU/1/22/1690 |
Gastro-resistant capsule, hard |
H01CB02 |
5.12.2022 |
||
5.12.2022 |
Qdenga |
dengue tetravalent vaccine (live, attenuated) |
|
EU/1/22/1699 |
Powder and solvent for solution for injection |
J07BX04 |
6.12.2022 |
||
9.12.2022 |
Livmarli |
maralixibat chloride |
|
EU/1/22/1704 |
Oral solution |
A05AX04 |
12.12.2022 |
||
9.12.2022 |
Locametz |
gozetotide |
|
EU/1/22/1692 |
Powder for solution for injection |
V09IX14 |
12.12.2022 |
||
9.12.2022 |
Pemetrexed Baxter |
pemetrexed |
|
EU/1/22/1705 |
Powder for concentrate for solution for infusion |
L01BA04 |
13.12.2022 |
||
9.12.2022 |
Pluvicto |
lutetium (177Lu) vipivotide tetraxetan |
|
EU/1/22/1703 |
Solution for injection or infusion |
V10XX05 |
12.12.2022 |
||
9.12.2022 |
Spevigo |
spesolimab |
|
EU/1/22/1688 |
Concentrate for solution for infusion |
L04AC22 |
12.12.2022 |
||
12.12.2022 |
Dimethyl Fumarate Teva |
dimethyl fumarate |
|
EU/1/22/1702 |
Gastro-resistant capsule, hard |
L04AX07 |
3.1.2023 |
||
12.12.2022 |
Eladynos |
abaloparatide |
|
EU/1/22/1706 |
Solution for injection |
H05AA04 |
13.12.2022 |
||
16.12.2022 |
Ebvallo |
Tabelecleucel |
|
EU/1/22/1700 |
dispersion for injection |
Pending |
16.12.2022 |
||
16.12.2022 |
Plerixafor Accord |
plerixafor |
|
EU/1/22/1701 |
Solution for injection |
L03AX16 |
19.12.2022 |
||
20.12.2022 |
Zynlonta |
loncastuximab tesirine |
|
EU/1/22/1695 |
Powder for concentrate for solution for infusion |
L01FX22 |
22.12.2022 |
— Modification of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
||
2.12.2022 |
Comirnaty |
|
EU/1/20/1528 |
2.12.2022 |
||
2.12.2022 |
DuoPlavin |
|
EU/1/10/619 |
5.12.2022 |
||
2.12.2022 |
Kaftrio |
|
EU/1/20/1468 |
5.12.2022 |
||
2.12.2022 |
Kalydeco |
|
EU/1/12/782 |
5.12.2022 |
||
2.12.2022 |
QINLOCK |
|
EU/1/21/1569 |
8.12.2022 |
||
2.12.2022 |
Sifrol |
|
EU/1/97/050 |
7.12.2022 |
||
2.12.2022 |
Spikevax |
|
EU/1/20/1507 |
7.12.2022 |
||
2.12.2022 |
Trizivir |
|
EU/1/00/156 |
5.12.2022 |
||
2.12.2022 |
Trogarzo |
|
EU/1/19/1359 |
14.12.2022 |
||
2.12.2022 |
Trydonis |
|
EU/1/18/1274 |
5.12.2022 |
||
2.12.2022 |
Zyclara |
|
EU/1/12/783 |
6.12.2022 |
||
5.12.2022 |
Shingrix |
|
EU/1/18/1272 |
6.12.2022 |
||
5.12.2022 |
Steglujan |
|
EU/1/18/1266 |
6.12.2022 |
||
5.12.2022 |
Xarelto |
|
EU/1/08/472 |
6.12.2022 |
||
9.12.2022 |
Abevmy |
|
EU/1/20/1515 |
14.12.2022 |
||
9.12.2022 |
Atriance |
|
EU/1/07/403 |
12.12.2022 |
||
9.12.2022 |
Aybintio |
|
EU/1/20/1454 |
13.12.2022 |
||
9.12.2022 |
Bortezomib Accord |
|
EU/1/15/1019 |
15.12.2022 |
||
9.12.2022 |
Deferiprone Lipomed |
|
EU/1/18/1310 |
12.12.2022 |
||
9.12.2022 |
Duaklir Genuair |
|
EU/1/14/964 |
12.12.2022 |
||
9.12.2022 |
Eklira Genuair |
|
EU/1/12/778 |
14.12.2022 |
||
9.12.2022 |
Erleada |
|
EU/1/18/1342 |
12.12.2022 |
||
9.12.2022 |
Eylea |
|
EU/1/12/797 |
13.12.2022 |
||
9.12.2022 |
Herzuma |
|
EU/1/17/1257 |
14.12.2022 |
||
9.12.2022 |
Insulin aspart Sanofi |
|
EU/1/20/1447 |
13.12.2022 |
||
9.12.2022 |
Insulin lispro Sanofi |
|
EU/1/17/1203 |
13.12.2022 |
||
9.12.2022 |
Onbevzi |
|
EU/1/20/1499 |
13.12.2022 |
||
9.12.2022 |
Oyavas |
|
EU/1/20/1510 |
12.12.2022 |
||
9.12.2022 |
Qarziba |
|
EU/1/17/1191 |
14.12.2022 |
||
9.12.2022 |
Retsevmo |
|
EU/1/20/1527 |
12.12.2022 |
||
9.12.2022 |
Riarify |
|
EU/1/18/1275 |
12.12.2022 |
||
9.12.2022 |
Spravato |
|
EU/1/19/1410 |
12.12.2022 |
||
9.12.2022 |
Suliqua |
|
EU/1/16/1157 |
13.12.2022 |
||
9.12.2022 |
Vaxelis |
|
EU/1/15/1079 |
13.12.2022 |
||
9.12.2022 |
Vydura |
|
EU/1/22/1645 |
12.12.2022 |
||
9.12.2022 |
Xydalba |
|
EU/1/14/986 |
12.12.2022 |
||
9.12.2022 |
Zirabev |
|
EU/1/18/1344 |
12.12.2022 |
||
12.12.2022 |
Alymsys |
|
EU/1/20/1509 |
13.12.2022 |
||
12.12.2022 |
Cablivi |
|
EU/1/18/1305 |
21.12.2022 |
||
12.12.2022 |
Dificlir |
|
EU/1/11/733 |
13.12.2022 |
||
12.12.2022 |
DuoPlavin |
|
EU/1/10/619 |
14.12.2022 |
||
12.12.2022 |
Dupixent |
|
EU/1/17/1229 |
13.12.2022 |
||
12.12.2022 |
Enhertu |
|
EU/1/20/1508 |
13.12.2022 |
||
12.12.2022 |
Karvezide |
|
EU/1/98/085 |
13.12.2022 |
||
12.12.2022 |
Kisqali |
|
EU/1/17/1221 |
13.12.2022 |
||
12.12.2022 |
Refixia |
|
EU/1/17/1193 |
13.12.2022 |
||
16.12.2022 |
Avastin |
|
EU/1/04/300 |
19.12.2022 |
||
16.12.2022 |
Bretaris Genuair |
|
EU/1/12/781 |
3.1.2023 |
||
16.12.2022 |
Brilique |
|
EU/1/10/655 |
19.12.2022 |
||
16.12.2022 |
Brimica Genuair |
|
EU/1/14/963 |
19.12.2022 |
||
16.12.2022 |
Caprelsa |
|
EU/1/11/749 |
19.12.2022 |
||
16.12.2022 |
Ceprotin |
|
EU/1/01/190 |
19.12.2022 |
||
16.12.2022 |
Combivir |
|
EU/1/98/058 |
19.12.2022 |
||
16.12.2022 |
Corbilta |
|
EU/1/13/859 |
20.12.2022 |
||
16.12.2022 |
DUAVIVE |
|
EU/1/14/960 |
20.12.2022 |
||
16.12.2022 |
DuoPlavin |
|
EU/1/10/619 |
19.12.2022 |
||
16.12.2022 |
Dupixent |
|
EU/1/17/1229 |
19.12.2022 |
||
16.12.2022 |
Eptifibatide Accord |
|
EU/1/15/1065 |
19.12.2022 |
||
16.12.2022 |
Granpidam |
|
EU/1/16/1137 |
19.12.2022 |
||
16.12.2022 |
Imatinib Accord |
|
EU/1/13/845 |
19.12.2022 |
||
16.12.2022 |
Imfinzi |
|
EU/1/18/1322 |
19.12.2022 |
||
16.12.2022 |
Inhixa |
|
EU/1/16/1132 |
22.12.2022 |
||
16.12.2022 |
Intuniv |
|
EU/1/15/1040 |
20.12.2022 |
||
16.12.2022 |
Iscover |
|
EU/1/98/070 |
19.12.2022 |
||
16.12.2022 |
Iscover |
|
EU/1/98/070 |
19.12.2022 |
||
16.12.2022 |
Iscover |
|
EU/1/98/070 |
19.12.2022 |
||
16.12.2022 |
Karvea |
|
EU/1/97/049 |
20.12.2022 |
||
16.12.2022 |
Levodopa/Carbidopa/Entacapone Orion |
|
EU/1/11/706 |
21.12.2022 |
||
16.12.2022 |
Lynparza |
|
EU/1/14/959 |
19.12.2022 |
||
16.12.2022 |
Moventig |
|
EU/1/14/962 |
21.12.2022 |
||
16.12.2022 |
Mvabea |
|
EU/1/20/1445 |
20.12.2022 |
||
16.12.2022 |
Myalepta |
|
EU/1/18/1276 |
21.12.2022 |
||
16.12.2022 |
Neulasta |
|
EU/1/02/227 |
20.12.2022 |
||
16.12.2022 |
Ocaliva |
|
EU/1/16/1139 |
19.12.2022 |
||
16.12.2022 |
Ozawade |
|
EU/1/21/1546 |
19.12.2022 |
||
16.12.2022 |
Plavix |
|
EU/1/98/069 |
19.12.2022 |
||
16.12.2022 |
Plavix |
|
EU/1/98/069 |
19.12.2022 |
||
16.12.2022 |
Plavix |
|
EU/1/98/069 |
19.12.2022 |
||
16.12.2022 |
Resolor |
|
EU/1/09/581 |
20.12.2022 |
||
16.12.2022 |
Rybelsus |
|
EU/1/20/1430 |
20.12.2022 |
||
16.12.2022 |
Sarclisa |
|
EU/1/20/1435 |
19.12.2022 |
||
16.12.2022 |
Saxenda |
|
EU/1/15/992 |
19.12.2022 |
||
16.12.2022 |
Spikevax |
|
EU/1/20/1507 |
19.12.2022 |
||
16.12.2022 |
Trajenta |
|
EU/1/11/707 |
19.12.2022 |
||
16.12.2022 |
Tresiba |
|
EU/1/12/807 |
20.12.2022 |
||
16.12.2022 |
Truvelog Mix 30 |
|
EU/1/22/1639 |
19.12.2022 |
||
16.12.2022 |
Twynsta |
|
EU/1/10/648 |
3.1.2023 |
||
16.12.2022 |
Zoledronic acid Accord |
|
EU/1/13/834 |
19.12.2022 |
||
19.12.2022 |
Inrebic |
|
EU/1/20/1514 |
20.12.2022 |
||
20.12.2022 |
Ibandronic acid Accord |
|
EU/1/12/798 |
22.12.2022 |
||
20.12.2022 |
Mvasi |
|
EU/1/17/1246 |
4.1.2023 |
||
20.12.2022 |
Rivaroxaban Accord |
|
EU/1/20/1488 |
22.12.2022 |
||
20.12.2022 |
Sarclisa |
|
EU/1/20/1435 |
21.12.2022 |
||
20.12.2022 |
Sirturo |
|
EU/1/13/901 |
21.12.2022 |
||
20.12.2022 |
Skytrofa |
|
EU/1/21/1607 |
21.12.2022 |
||
22.12.2022 |
Comirnaty |
|
EU/1/20/1528 |
22.12.2022 |
||
22.12.2022 |
Paxlovid |
|
EU/1/22/1625 |
22.12.2022 |
— Withdrawal of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
||
5.12.2022 |
Trogarzo |
|
EU/1/19/1359 |
5.1.2023 |
||
9.12.2022 |
NeuroBloc |
|
EU/1/00/166 |
12.12.2022 |
— Issuing of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council): Accepted
Date of the decision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
||
20.12.2022 |
NEOLEISH |
Canine leishmaniasis vaccine (recombinant DNA plasmid) |
|
EU/2/22/290 |
Nasal spray, solution |
Pending |
21.12.2022 |
— Modification of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council): Accepted
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
||
2.12.2022 |
CYTOPOINT |
|
EU/2/17/205 |
5.12.2022 |
||
2.12.2022 |
Fevaxyn Pentofel |
|
EU/2/96/002 |
6.12.2022 |
||
2.12.2022 |
Solensia |
|
EU/2/20/269 |
5.12.2022 |
||
2.12.2022 |
Tulissin |
|
EU/2/20/252 |
6.12.2022 |
||
2.12.2022 |
Zenalpha |
|
EU/2/21/279 |
7.12.2022 |
||
9.12.2022 |
Convenia |
|
EU/2/06/059 |
14.12.2022 |
||
9.12.2022 |
Zeleris |
|
EU/2/17/210 |
14.12.2022 |
||
13.12.2022 |
Innovax-ND-ILT |
|
EU/2/20/256 |
14.12.2022 |
||
13.12.2022 |
Versican Plus DHPPi/L4R |
|
EU/2/14/163 |
14.12.2022 |
||
15.12.2022 |
Exzolt |
|
EU/2/17/212 |
20.12.2022 |
||
15.12.2022 |
Librela |
|
EU/2/20/261 |
21.12.2022 |
||
15.12.2022 |
NEXGARD SPECTRA |
|
EU/2/14/177 |
16.12.2022 |
||
15.12.2022 |
Porcilis PCV M Hyo |
|
EU/2/14/175 |
20.12.2022 |
||
15.12.2022 |
Simparica Trio |
|
EU/2/19/243 |
20.12.2022 |
||
15.12.2022 |
Simparica Trio |
|
EU/2/19/243 |
20.12.2022 |
||
15.12.2022 |
UBAC |
|
EU/2/18/227 |
21.12.2022 |
||
15.12.2022 |
Versican Plus Pi/L4R |
|
EU/2/14/173 |
16.12.2022 |
||
16.12.2022 |
Equip WNV |
|
EU/2/08/086 |
20.12.2022 |
||
20.12.2022 |
Lydaxx |
|
EU/2/20/253 |
21.12.2022 |
||
20.12.2022 |
Novem |
|
EU/2/04/042 |
22.12.2022 |
||
20.12.2022 |
Onsior |
|
EU/2/08/089 |
21.12.2022 |
||
20.12.2022 |
ProteqFlu |
|
EU/2/03/037 |
22.12.2022 |
||
20.12.2022 |
ProteqFlu-Te |
|
EU/2/03/038 |
22.12.2022 |
||
20.12.2022 |
Rabitec |
|
EU/2/17/219 |
21.12.2022 |
||
20.12.2022 |
RHINISENG |
|
EU/2/10/109 |
22.12.2022 |
||
20.12.2022 |
Suprelorin |
|
EU/2/07/072 |
23.12.2022 |
||
20.12.2022 |
Tulaven |
|
EU/2/20/251 |
21.12.2022 |
Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:
European Medicines Agency |
Domenico Scarlattilaan 6 |
1083 HS Amsterdam |
NETHERLANDS |